Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the ... market share from traditional sources as customers of these products recognize ...

DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization ...